Beam Therapeutics Inc. (BEAM) short interest & options flow
NASDAQBeam Therapeutics just posted its Q3 results, and the stock has gained 5.7% over the past week to $26.33, outperforming most of its gene-editing peers at a moment when the analyst community is sending sharply mixed signals on valuation. The short position has continued its gradual retreat. Short interest has fallen to 26.0% of the free float, down from the mid-October peak of…
BEAM short interest surges 31% in one week to 28.6% of float, highest since late May, as clinical-stage gene editor faces mounting pressure from short sellers despite upcoming regulatory catalysts.
- Market cap
- $2.69B
- Next earnings
- 24 Feb 2027
Key data as of 10 Nov 2026
BEAM news and analysis
RSSNo long-form analysis yet for BEAM. Pulse alerts and the live data picture are available on ORTEX.
Open BEAM on ORTEX →Want the live picture for BEAM?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BEAM — free to start on ORTEX.
Sign up for free →Open BEAM on ORTEX